Hospital
Saddleback Memorial Medical Center
Saddleback Memorial Medical Center was paid $2.89M by Medicaid between Jan 2018 and Dec 2024, across 184 billing codes. Its largest line is 0450, Emergency room services — 11% of everything it billed.
33Billing provider infoSADDLEBACK MEMORIAL MEDICAL CENTER
LAGUNA HILLS, CA 92653
LAGUNA HILLS, CA 92653
33aNPI1275576381assigned 06/14/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$2.89M
24GClaims341,289
24DCodes billed184
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#247 of 410
Median peer was paid$6.90M
This provider vs. median0.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 46,538 | $288K | |
| 2019 | 51,374 | $350K | |
| 2020 | 49,161 | $296K | |
| 2021 | 56,060 | $273K | |
| 2022 | 64,309 | $363K | |
| 2023 | 52,971 | $569K | |
| 2024incomplete | 20,876 | $749K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 11% | 31,932 | 28,004 | $318K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 11% | 2,078 | 2,022 | $305K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 8.1% | 2,779 | 2,428 | $233K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 5.6% | 8,959 | 8,416 | $163K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.7% | 7,283 | 6,377 | $136K |
| A0429 | Emergency ambulance ride, basic life supportAmbulance service, basic life support, emergency transport (bls-emergency) | 4.0% | 5,692 | 3,871 | $115K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.0% | 3,189 | 2,941 | $86K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.9% | 2,519 | 2,408 | $84K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 2.9% | 3,030 | 2,697 | $84K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.3% | 8,919 | 7,827 | $65K |
| 80053 | Comprehensive metabolic panel | 2.2% | 17,515 | 15,203 | $64K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.2% | 2,537 | 2,345 | $64K |
172 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 2.1% | 5,381 | $61K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.8% | 3,062 | $53K |
| 77063 | Screening digital breast tomosynthesis, bilateral | 1.7% | 8,571 | $49K |
| J3490 | Unclassified drugs | 1.7% | 18,367 | $48K |
| 77066 | Tomosynthesis, mammo | 1.6% | 1,807 | $47K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.6% | 2,247 | $47K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 16,960 | $44K |
| J7030 | Infusion, normal saline solution , 1000 cc | 1.4% | 7,591 | $39K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.3% | 4,546 | $38K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 1.3% | 1,444 | $37K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.3% | 4,534 | $36K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.2% | 1,001 | $34K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.1% | 286 | $33K |
| 71045 | Radiologic examination, chest; single view | <1% | 6,561 | $29K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,317 | $28K |
| 99283 | Emergency room visit (moderate) | <1% | 1,841 | $28K |
| 76642 | <1% | 2,250 | $27K | |
| 99199 | Unlisted special service, procedure or report | <1% | 598 | $25K |
| 77065 | Tomosynthesis, mammo | <1% | 1,363 | $24K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,723 | $22K |
| 84484 | <1% | 6,095 | $21K | |
| 76641 | <1% | 892 | $20K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 2,951 | $19K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,040 | $18K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,057 | $18K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,167 | $17K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,476 | $17K |
| 99285 | Emergency room visit (most serious) | <1% | 1,803 | $13K |
| 83690 | <1% | 5,301 | $13K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,682 | $11K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,989 | $11K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,035 | $11K |
| 77080 | <1% | 1,846 | $10K | |
| 83880 | <1% | 1,229 | $10K | |
| 99284 | Emergency room visit (serious) | <1% | 1,334 | $8K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 148 | $7K |
| 81025 | <1% | 4,847 | $7K | |
| 84145 | <1% | 1,057 | $7K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 362 | $7K |
| 81001 | <1% | 6,945 | $7K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 11,053 | $7K |
| 96376 | <1% | 1,718 | $6K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,250 | $6K |
| 83605 | <1% | 1,910 | $6K | |
| 93971 | <1% | 196 | $6K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 418 | $5K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 753 | $5K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,196 | $5K |
| 85027 | <1% | 2,987 | $5K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,928 | $5K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 830 | $4K |
| G0378 | Hospital observation service, per hour | <1% | 21 | $4K |
| 85379 | <1% | 1,247 | $4K | |
| 0270 | <1% | 20,188 | $4K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 869 | $3K |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 197 | $3K |
| 87486 | <1% | 288 | $3K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 610 | $3K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,069 | $3K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 834 | $3K |
| 76830 | Ultrasound, transvaginal | <1% | 246 | $3K |
| 85730 | <1% | 1,842 | $3K | |
| 87581 | <1% | 289 | $3K | |
| 87040 | <1% | 741 | $3K | |
| 80143 | <1% | 296 | $3K | |
| 80179 | <1% | 292 | $3K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 291 | $3K |
| 86140 | <1% | 1,838 | $3K | |
| 85610 | <1% | 2,245 | $2K | |
| 87400 | <1% | 554 | $2K | |
| 84702 | <1% | 729 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,455 | $2K |
| 81003 | <1% | 2,875 | $2K | |
| 82947 | <1% | 3,494 | $2K | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 14 | $2K |
| 73610 | <1% | 227 | $2K | |
| 85007 | <1% | 2,081 | $2K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 27 | $2K |
| Z7502 | <1% | 38 | $1K | |
| 82803 | <1% | 342 | $1K | |
| 73030 | <1% | 226 | $1K | |
| 71250 | <1% | 67 | $1K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 133 | $1K |
| 73630 | <1% | 162 | $1K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 37 | $1K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 53 | $1K |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 307 | $1K |
| 73562 | <1% | 181 | $1K | |
| 87186 | <1% | 370 | $968.44 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 549 | $960.14 |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 77 | $932.61 |
| 73564 | <1% | 74 | $911.53 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 674 | $876.42 |
| J2704 | Injection, propofol, 10 mg | <1% | 305 | $865.61 |
| 97161 | <1% | 49 | $832.57 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 224 | $796.15 |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 119 | $759.16 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 202 | $740.15 |
| 36416 | <1% | 1,193 | $697.64 | |
| 83735 | <1% | 345 | $673.01 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 17 | $632.00 |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 19 | $627.39 |
| 70486 | <1% | 30 | $620.07 | |
| 0272 | <1% | 1,852 | $577.00 | |
| 73110 | <1% | 69 | $559.72 | |
| 73130 | <1% | 77 | $479.57 | |
| 71020 | <1% | 41 | $474.43 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 509 | $443.41 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 29 | $421.13 |
| Z9725 | <1% | 12 | $360.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 71 | $337.80 |
| 90715 | <1% | 27 | $335.82 | |
| 71010 | <1% | 51 | $327.58 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 12 | $313.48 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 12 | $312.68 |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 14 | $309.60 |
| 84703 | <1% | 417 | $287.17 | |
| J1815 | Injection, insulin, per 5 units | <1% | 71 | $232.49 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 17 | $226.18 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 138 | $218.16 |
| 0160 | <1% | 850 | $198.80 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 22 | $196.11 |
| 0301 | <1% | 752 | $191.85 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 18 | $178.42 |
| A4648 | Tissue marker, implantable, any type, each | <1% | 76 | $163.88 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 24 | $157.57 |
| 0250 | <1% | 6,874 | $147.79 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 66 | $126.64 |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 18 | $83.12 |
| 86901 | <1% | 75 | $68.31 | |
| 86900 | <1% | 75 | $61.20 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 47 | $57.98 |
| 0710 | <1% | 102 | $52.26 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 24 | $38.27 |
| 82728 | <1% | 15 | $36.77 | |
| 83874 | <1% | 17 | $34.87 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 38 | $33.69 |
| 74018 | <1% | 13 | $33.50 | |
| 82550 | <1% | 14 | $23.37 | |
| 83615 | <1% | 13 | $21.68 | |
| 76536 | <1% | 39 | $21.37 | |
| 87077 | <1% | 22 | $20.91 | |
| 85652 | <1% | 13 | $12.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 28 | $9.83 |
| 19083 | <1% | 20 | $7.42 | |
| 0300 | 0% | 71 | $0.00 | |
| 0403 | 0% | 175 | $0.00 | |
| 0351 | 0% | 54 | $0.00 | |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | 0% | 1,333 | $0.00 |
| 0320 | 0% | 86 | $0.00 | |
| 99001 | 0% | 16 | $0.00 | |
| 0360 | 0% | 29 | $0.00 | |
| 0402 | 0% | 88 | $0.00 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 0% | 27 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 16 | $0.00 |
| 0302 | 0% | 34 | $0.00 | |
| 78815 | Positron emission tomography (PET) for limited area imaging | 0% | 12 | $0.00 |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | 0% | 13 | $0.00 |
| 0762 | 0% | 33 | $0.00 | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | 0% | 12 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 16 | $0.00 |
| 0949 | 0% | 189 | $0.00 | |
| 0305 | 0% | 366 | $0.00 | |
| 0636 | 0% | 385 | $0.00 | |
| 0306 | 0% | 301 | $0.00 | |
| 0611 | 0% | 19 | $0.00 | |
| 0352 | 0% | 97 | $0.00 | |
| 0324 | 0% | 98 | $0.00 | |
| Q0222 | Injection, bebtelovimab, 175 mg | 0% | 13 | $0.00 |
| 0307 | 0% | 21 | $0.00 | |
| 0610 | 0% | 14 | $0.00 | |
| 0401 | 0% | 68 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFINCH, CHRIS (CHIEF COMPLIANCE OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Long Beach Memorial Medical | Long Beach, CA | $47.90M |
| Long Beach Memorial Medical | Long Beach, CA | $21.31M |
| Long Beach Memorial Medical | Long Beach, CA | $1.89M |
| Long Beach Memorial Medical | Long Beach, CA | $1.09M |
| Long Beach Memorial Medical | Long Beach, CA | $1.04M |
| Long Beach Memorial Medical Center, INC | Long Beach, CA | $802K |
| Long Beach Memorial Medical | Laguna Hills, CA | $1K |
| Long Beach Memorial Medical | Long Beach, CA | $402.67 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.